Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 2394

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 9B
Chunk 2394
---
ington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.

Our Board of Directors believes
that Mr. Lucera’s experience and perspective advising the Company and other life sciences companies on strategic transactions and
financings, as well as his depth of operating and senior management experience in our industry, provide him with the qualifications and
skills to serve as a director.

Yoori Lee, Director

Yoori Lee joined our Board of
Directors in January 2018. Ms. Lee serves on our compensation committee and nominating committee. She has served as Co-founder and President
of Trio Health Advisory Group, Inc. since 2013. Trio Health’s mission is to improve the quality of care in patient outcomes through
coordinating the efforts of all patient care stakeholders. Prior to Trio Health, Ms. Lee spent over 15 years at Leerink Partners LLC,
a leading healthcare investment bank, where she was Managing Director, and Director of MEDACorp Services. Additionally, she helped found
the MEDACorp network, a cadre of experts including more than 35,000 healthcare professionals in diverse areas of practice such as clinical
medicine, biomedical research, regulatory affairs, public policy, healthcare administration and healthcare information technology.

Our Board of Directors believes
that Ms. Lee’s experience and perspective advising the Company as well as her experience with Leerink Partners LLC and MEDACorp.
provide her with the qualifications and skills to serve as a director.

85

Dr. William Forbes, Director

Dr. William Forbes joined our
Board of Directors in August 2018 and serves on our nominating committee. He brings to our Board of Directors more than 30 years of pharmaceutical
product development experience and, working with health authorities in the U.S. and Europe, has contributed to numerous marketing approvals
spanning a diverse range of therapeutic areas. Dr. Forbes has served as the Chief Development Officer of Trevi Therapeutics, a clinical-stage
pharmaceutical company focused on serious neurologically mediated diseases since February 2021. Prior to joining Trevi, Dr. Forbes was
at Salix Pharmaceuticals as the Chief Development Officer and also Head of Medical and R&D from February 2015 to June 2015. Prior
to Salix, Dr. Forbes spent 15 years in Clinical Development & Regulatory Affairs and Clinical Research at a number of global pharmaceutical
companies.

Our Board of Directors believes
that Dr. Forbes’